drugset / Trial / NCT00135057

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

NCT00135057

Phase 3 Completed 281 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus insulin regimen (based on carbohydrate counting) versus a fixed bolus insulin regimen, with insulin glargine as basal insulin in both arms of the study.

Timeline

Start
2004-04
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic
Background insulin glargine Protein / enzyme biologic